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associated diarrhea.
Administration of GSB was well tolerated and safe, and with
no associated fungemia. The administration of GSB in the
immediate pre-transplant period did not impact LOS, inci-
dence and severity of mucositis, or incidence and volume of
diarrhea. Complete analysis and subgroup analysis are being
performed and will be presented at the meeting.
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Background: Vaccine-preventable diseases continue to pose
a risk to HSCT recipients, thus guidelines recommend routine
vaccination after HSCT. Pediatric data is limited regarding
vaccine immunogenicity post-HSCT and may contribute to
inconsistent vaccination practices.
Objective: Prospective, observational study to determine the
immunogenicity of hepatitis B, tetanus, and pneumococcal
vaccination in children after HSCT. Secondary objective was
to evaluate correlation with T&B cell numbers.
Patients and Methods: Children receiving a HSCT from
January 2010 thru October 2012were prospectively followed.
Three doses of Hepatitis, PCV 13, and Pentacel were given per
guidelines two months apart. Pre and post vaccine-speciﬁc
antibodies and T&B cell studies were performed at 6 and 12
months post-HSCT.
Results: Compliance with current vaccine recommendations
occurred in 15 of 33 (45 %) subjects. Of the 15 subjects, 12
were evaluable receiving vaccinations and lab draws
according to the predeﬁned schedule. Patient characteristics
are described in Table 1.
Time to immunization post HSCT was a median of 197
days [180-404]. 2/12 subjects were chronic GVHD patients on
immunosuppression at the time of re-vaccination. One of
these patients did not respond to vaccination. Protective
antibody levels were found for tetanus in 83% of subjects
(median of 2.6 IU/mL [range 0.1-7]) and 69% of patients for
hepatitis. 4 evaluable subjects responded to at least 1Table 1
Patient Characteristics
Male 8 (62%)
Age at transplant 7.8 (0.6-18.9)
Transplant Type
Allogeneic 11 (85%)
Autologous 2 (15%)
Donor Source
Bone marrow 7 (54%)
Peripheral blood 3 (23%)
Umbilical cord blood 3 (23%)
Preparative Regimen
Myeloablative 10 (77%)
Serotherapy 6 (60%)
Non-myeloblative 3 (23%)
Serotherapy 2 (67%)
GVHD Prophylaxis
CNI/MTX 6 (60%)
CNI/MMF 4 (40%)pneumococcal serotype, 2 of 4 (50%) to at least 6 serotypes;
3, 4, 6B, and 19F were most immunogenic. There was no
correlation between total peripheral WBC or CD3, CD8, CD19
numbers and tetanus antibody concentrations.
Conclusions: Despite the small sample size in our cohort,
hepatitis, tetanus, and pneumococcal vaccination was
immunogenic in a majority of subjects when given 6 months
post HSCT. Pneumococcal serotypes cited to cause invasive
disease post HSCT were most immunogenic, but additional
data is needed.319
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Advances in autologous and allogeneic hematopoietic stem
cell transplantation (HSCT) over the past 20 years may have
had an impact on the morbidity and mortality associated
with infections post-transplant. We sought to retrospectively
analyze the epidemiology and risk factors for bacterial,
fungal, viral, and parasitic infections 0-30 days post-trans-
plant in a cohort of 385 autologous and 759 allogeneic
pediatric HSCT recipients transplanted in a single institution
between1990 to 2009. Risk factors were evaluated using
logistic regression. Infections occurred in 98 (25%) autolo-
gous compared to 307 (40%) allogeneic HSCT patients. Gram-
positive bacterial infections were more prevalent than gram-
negative bacterial infections in both autologous (P ¼ .003)
and allogeneic (P < .0001) HSCT patients. Bacteremia
occurred in 31 (8%) autologous and 59 (8%) allogeneic HSCT
patients. Autologous HSCT patients with a diagnosis of
leukemia were at a higher risk for bacterial infections
compared to those with solid tumors (P ¼ .004, OR 2.80, 95%
CI 1.39-5.66). Infections due to fungal and parasitic patho-
gens in autologous HSCT patients were uncommon, and
occurred exclusively prior to 2000. Candidemiawas detected
in 26 (3%) and aspergillosis in 49 (6%) allogeneic recipients.
Herpes-Simplex virus was the most common cause of viral
infections in both autologous and allogeneic recipients.
Cytomegalovirus donor/recipient status increased risk for all
viral infections for allogeneic HSCT recipients (P ¼ .0004).
Only 3 (0.8%) deaths were attributed to infection after
autologous HSCT. All occurred prior to 2000 in patients
transplanted for acute myeloid leukemia. There were 8 (1%)
allogeneic HSCT patients who died of infections 0-30 days
post-transplant. This is the largest retrospective study on the
changing epidemiology of infections after autologous and
allogeneic HSCT in children and adolescents.320
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